Furthermore, under the settlement agreement, Mulleady is subject to a $250,000 suspended judgment as equitable monetary relief. The suspension will be lifted following a final unappealable judgment of contempt against him. He will pay the monetary relief within 90 days of delivery of instructions by a Designated State Representative.
Moreover, Mulleady is prohibited from working for, consulting for, or controlling a pharmaceutical company for 7 years.
Shkreli will face trial later this month
The trial against Shkreli will start later this December. Shkreli is currently in prison for securities fraud. He allegedly masterminded the scheme to monopolize Daraprim and while in prison he directed his company to continue its anti-competitive practices.
In a statement, FTC Chairwoman Lina Khan said, “Today’s action puts money back in the pockets of drug patients fleeced by a monopolistic scheme. Martin Shkreli masterminded an elaborate plan to dramatically jack up the price of life-saving drug Daraprim by blocking cheaper options. While litigation against Shkreli continues, the order shuts down the illegal enterprise run by his companies, Vyera and Phoenixus, and bans his associate from the industry. This strong relief sets a new standard and puts corporate leaders on notice that they will face severe consequences for ripping off the public by wantonly monopolizing markets.”
